Results for "BPaL regimen MDR-TB"2

Showing 1–2 of 2 documents

Sorted by hybrid relevance (keyword + semantic via RRF)

Clinical trialMDR-TB2026-03
Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment
Marco Schiuma, Souleymane Hassane Harouna
Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge to global public health. Globally, the World Health Organization (WHO) estimates the number at 400,000 patients with MDR-TB for 2023. Only 44% were diagnosed and put on treatment, the therapeutic success rat…
Clinical trialMDR-TB2022-05
BPaL(M) Regimen for the Treatment of MDR/RR-TB
Asan Medical Center
…objective of this study is to analyze the efficacy of a new regimen using Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin for 24 weeks or Bedaquiline, Pretomanid, Linezolid for 26 weeks for the treatment of MDR/RR-TB through the clinical trial. The BPaL (Bedaquiline, Pretom…

Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment